Join WhatsApp

Join Now

Join Telegram

Join Now

Lupin Ltd Share Price Target 2025 to 2040 Forecast & Fundamentals

By Suraj Sharma

Published on:

Lupin Ltd Share Price Target

Here, we are going to share Lupin Ltd Share Price Target 2025 to 2040 on the basis of its fundamental and technical analysis.

Lupin Ltd is a well known pharmaceutical company headquartered in Mumbai, India.

It is one of the largest pharma companies in the country, known for manufacturing and marketing a broad range of generic and branded formulations, APIs, and biotechnology products.

With a global presence spanning over 100 countries, Lupin plays an important role in the healthcare industry.

Lupin Ltd Company Overview

  • Established Year: 1968
  • Headquarters: Mumbai, Maharashtra, India
  • Business: Pharmaceutical manufacturing and distribution
  • Growth: Lupin has grown into a global pharmaceutical player with strong market presence in key therapeutic areas and significant investments in research and development.
  • Employees: Approximately 17,000
  • Location: Operates in India, United States, Europe, and various other regions.
  • Markets they serve: Lupin serves markets across India, North America, Europe, Japan, and emerging markets.

Lupin Ltd Share Key Information

Company NameLupin Ltd
HeadquartersMumbai, Maharashtra
SectorsPharmaceuticals & Drugs
Market Cap₹ 98,167.61 Cr.
No. of Shares45.61 Cr.
Book Value₹468.70
Dividend Yield0.37%
ROCE14.33%
ROE12%
Face Value₹2
Sales Growth30.27%
Profit Growth447.05%
Debt₹18.13 Cr
Cash₹138.64 Cr

Lupin Ltd Business Sector

Lupin’s business model is centered around the development, manufacturing, and sale of a wide variety of generic and branded pharmaceuticals. It operates in several key areas:

  • Generics: Lupin is a major player in the global generic drug market, providing cost-effective alternatives to branded drugs.
  • Branded Formulations: The company also focuses on branded formulations, especially in markets like India and Japan.
  • APIs: Active Pharmaceutical Ingredients (APIs) are a significant part of its portfolio, supplying both internal needs and external customers.
  • Research and Development: Lupin invests heavily in R&D to innovate in areas such as biotechnology, biosimilars, and new chemical entities (NCEs).

Board Members

  • Vinita Gupta: Chief Executive Officer
  • Nilesh Gupta: Managing Director
  • Kamlesh Shah: Independent Director
  • Yashwant Mahadik: Independent Director
  • Raghunandan Deshpande: Independent Director
  • Manish Gupta: Non-Executive Director

Lupin Ltd Share Quarterly Results

PARTICULARSMar 2024Jun 2024
Net Sales 3,395.884,167.63
Total Expenditure 2,695.532,968.82
Operating Profit 700.351,198.81
Other Income 31.3439.08
Interest 13.4913.55
Depreciation 290.04141.42
Exceptional Items 00
Profit Before Tax 428.161,082.92
Tax 44.08193.74
Profit After Tax 384.08889.18
Adjusted EPS (Rs) 8.4319.50

Lupin Ltd Company Profits and Losses

PARTICULARSMar 2023Mar 2024
Net Sales 11,258.8314,666.50
Total Expenditure 10,294.9311,227.12
Operating Profit 963.903,439.38
Other Income 210.02126.41
Interest 98.4456.35
Depreciation 548.34724.75
Exceptional Items 00
Profit Before Tax 527.142,784.69
Tax 101.93458.60
Net Profit 425.212,326.09
Adjusted EPS (Rs.) 9.3551.04

Lupin Ltd Share Price Target 2025-2040

YearInitial TargetYear-End Target
2025₹2361₹2465
2026₹2485₹2733
2027₹2716₹2976
2028₹2950₹3183
2029₹3202₹3502
2030₹3525₹3685
2035₹4250₹4890
2040₹6250₹7550

Lupin Ltd Share Price Target 2025

Year/MonthPredicted Target
January 2025 ₹2361
February 2025 ₹2368
March 2025 ₹2375
April 2025 ₹2379
May 2025 ₹2385
June 2025 ₹2392
July 2025 ₹2404
August 2025₹2412
September 2025 ₹2419
October 2025₹2433
November 2025₹2456
December 2025 ₹2465

Lupin Ltd Share Price Target 2026

Year/MonthPredicted Target
January 2026 ₹2485
February 2026 ₹2507
March 2026 ₹2534
April 2026₹2541
May 2026 ₹2550
June 2026 ₹2590
July 2026 ₹2587
August 2026₹2628
September 2026 ₹2674
October 2026₹2724
November 2026₹2732
December 2026 ₹2733

Lupin Ltd Share Price Target 2027

Year/MonthPredicted Target
January 2027 ₹2716
February 2027 ₹2739
March 2027 ₹2767
April 2027 ₹2774
May 2027 ₹2784
June 2027 ₹2824
July 2027 ₹2821
August 2027 ₹2858
September 2027 ₹2906
October 2027₹2958
November 2027₹2966
December 2027 ₹2976

Lupin Ltd Share Price Target 2028

Year/MonthPredicted Target
January 2028 ₹2950
February 2028 ₹2972
March 2028 ₹3002
April 2028 ₹3012
May 2028 ₹3058
June 2028 ₹3056
July 2028 ₹3093
August 2028₹3144
September 2028 ₹3190
October 2028₹3200
November 2028₹3199
December 2028 ₹3183

Lupin Ltd Share Price Target 2029

Year/MonthPredicted Target
January 2029 ₹3202
February 2029 ₹3237
March 2029 ₹3245
April 2029 ₹3251
May 2029 ₹3292
June 2029 ₹3290
July 2029 ₹3323
August 2029₹3423
September 2029 ₹3432
October 2029₹3465
November 2029₹3492
December 2029 ₹3502

Lupin Ltd Share Price Target 2030

Year/MonthPredicted Target
January 2030 ₹3525
February 2030 ₹3529
March 2030 ₹3548
April 2030 ₹3569
May 2030 ₹3578
June 2030 ₹3561
July 2030 ₹3582
August 2030₹3602
September 2030 ₹3612
October 2030₹3652
November 2030₹3665
December 2030 ₹3685

Lupin Ltd Share Price Target 2035

Year/MonthPredicted Target
January 2035 ₹4250
April 2035 ₹4456
July 2035 ₹4560
October 2035₹4750
December 2035 ₹4890

Lupin Ltd Share Price Target 2040

Year/MonthPredicted Target
January 2040 ₹6250
April 2040 ₹6480
July 2040 ₹6920
October 2040₹7120
December 2040 ₹7550

Lupin Ltd Shareholding Pattern

TermsPercentage
Promoters46.98%
FIIs19.32%
DIIs26.78%
Others0%
Public6.92%

Lupin Ltd Company Competitors

  • Dr Reddy’s Lab
  • Torrent Pharma
  • Mankind Pharma
  • Aurobindo Pharma
  • Alkem Laboratories

Bull Case of Lupin Ltd (Reasons to Invest)

Strong Market Presence: Lupin has a robust presence in key markets like the United States and India, which contributes significantly to its revenue.

R&D Capabilities: Continuous investment in R&D is likely to lead to new product launches and expansion into new therapeutic areas.

Regulatory Approvals: Multiple regulatory approvals for new products can drive revenue growth.

Debt Management: Lupin has a strong balance sheet with low debt, making it financially stable.

Bear Case of Lupin Ltd (Risks Involved)

Regulatory Challenges: Frequent regulatory scrutiny and compliance issues can impact product launches and sales.

Competition: High competition in the generic drug market can pressure pricing and margins.

Dependence on Key Markets: Over-reliance on the U.S. market makes the company vulnerable to regulatory and pricing changes.

Currency Fluctuations: Global operations expose the company to currency risks, which can affect profitability.

Lupin Ltd Share Price Target: FAQ

What will be the target of Lupin Ltd Share for the year 2025?

By the end of the year 2025, its share price can reach ₹2465.

What will be the target of Lupin Ltd Share for the year 2026?

By the end of the year 2026, its share price can reach ₹2733.

What will be the target of Lupin Ltd Share for the year 2027?

By the end of the year 2027, its share price can reach ₹2976.

What will be the target of Lupin Ltd Share for the year 2028?

By the end of the year 2028, its share price can reach ₹3183.

What will be the target of Lupin Ltd Share for the year 2029?

By the end of the year 2029, its share price can reach ₹3502.

What will be the target of Lupin Ltd Share for the year 2030?

By the end of the year 2030 its share price can reach ₹3685.

What is the Current market cap of Lupin Ltd company?

At present the market cap of this company is ₹ 98,167.61 Cr.

What is the NSE symbol of Lupin Ltd company?

The symbol of this company in NSE exchange is LUPIN.

What is the BSE symbol of Lupin Ltd company?

The symbol of this company in BSE exchange is 500257.

Suraj Sharma

SK Sharma is a senior content writer with 5 years of experience, having worked with top media outlets like Network 18 and Dainik Bhaskar. He holds a Post Graduate Diploma in English Journalism and currently writes full-time for Techiesk.

Leave a Comment